Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Prior treatment

• Individuals who score a 3, 4, or 5 within the previous month on the suicidal ideation section of the Columbia Suicide Severity Rating Scale (CSSRS), have any suicidal behavior (not including Not Suicidal Self Injury) within the previous 3 months, or are, in the opinion of the investigator, at too high of a risk for suicide to be safety treated in a randomized trial in which they may not be treated with clozapine

Other illness

• An unstable of serious medical or neurological condition including a myeloproliferative disorder or condition that surprises the bone marrow
• A history of intolerance/allergy to clozapine (e.g., agranulocytosis, small bowel obstruction, or myocarditis)
• A history of intellectual impairment

Other

• pregnant or lactating women; women who are able to become pregnant but who are not willing to sue effective methods of birth control
• Documented intolerance to or lack of any therapeutic benefit with clozapine after a full trial

• Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of schizophrenia or schizoaffective disorder by the Structured Clinical Interview for DSM-5 (SCID-5)
• commission of a minor or serious act of violence as measured by the MCVI in the last six months
• willing and able to provide informed consent
• medically stable in judgment of physician providing study treatment
• appropriate for treatment with either clozapine or TAU, i.e., that there is clinical equipoise between the two treatment options. Individuals who are currently medication free or on any antipsychotic, with the exception of clozapine or long-acting injectable medication with a dosing interval of more than 30 days will be eligible